Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C74012
http://purl.obolibrary.org/obo/NCIT_C74012
Preferred Name

Rivoceranib Mesylate
Definitions
The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
prefLabel
Rivoceranib Mesylate
label
Rivoceranib Mesylate
PDQ_Closed_Trial_Search_ID
592508
code
C74012
Has_Target
prefixIRI
NCIT:C74012
in_subset
Display_Name
Rivoceranib Mesylate
Preferred_Name
Rivoceranib Mesylate
FDA_UNII_Code
TK02X14ASJ
Contributing_Source
CTRP
FDA
Maps_To
Rivoceranib Mesylate
CAS_Registry
1218779-75-9
NCI_Drug_Dictionary_ID
592508
Legacy Concept Name
Rivoceranib Mesylate
Has_Free_Acid_Or_Base_Form
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
592508
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C2346836
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display